{
  "url": "https://struct.news/briefs/celcuity-cut-trial-costs-but-six-month-cash-burn-climbed-to-1105-million",
  "title": "Celcuity cut trial costs, but six-month cash burn climbed to $110.5 million",
  "summary": "A $422.9 million financing lifted cash to $182.0 million even as operating losses widened and diluted shares rose 25.5%.",
  "published_at": "2026-08-13T21:21:05.920390+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Celcuity Inc.",
    "ticker": "CELC",
    "cik": "1193125",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-13",
    "accession": "0001193125-26-349608",
    "url": "https://www.sec.gov/Archives/edgar/data/1603454/000119312526349608/celc-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-08-14",
    "url": "https://www.sec.gov/Archives/edgar/data/1603454/000164117225024148/form10-q.htm"
  },
  "reported_figures": [
    {
      "group": "Cash cushion, financed",
      "label": "Last close",
      "value": 86.77,
      "display": "$86.77",
      "unit": "usd_per_share",
      "period": "2026-08-13",
      "detail": null,
      "source": {
        "kind": "market_data",
        "label": "Observed market close",
        "as_of": "2026-08-13"
      }
    },
    {
      "group": "Cash cushion, financed",
      "label": "One-day move",
      "value": -5.766724587315375,
      "display": "-5.8%",
      "unit": "percent",
      "period": "2026-08-13",
      "detail": null,
      "source": {
        "kind": "market_data",
        "label": "Observed market close",
        "as_of": "2026-08-13"
      }
    }
  ],
  "watch_next": [
    {
      "type": "product_pipeline",
      "statement": "VIKTORIA-1 Phase 3 trial costs fell materially during the six-month period, reducing clinical spending alongside lower license milestone costs.",
      "importance": "medium",
      "evidence": "The decrease was primarily due to a $12.1 million decrease in clinical trial costs, which was primarily driven by decreased costs for the VIKTORIA-1 Phase 3 clinical trial, and a $5.0 million decrease in license milestone costs.",
      "source_date": "2026-08-13"
    }
  ],
  "related_tickers": [
    "CELC"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}